References
Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67(3):423–434. https://doi.org/10.1007/s00262-017-2090-z
Pileri A, Agostinelli C, Sessa M, Quaglino P, Santucci M, Tomasini C, Grandi V, Fava P, Astrua C, Righi S, Patrizi A, Pileri SA, Pimpinelli N (2017) Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch 470(5):575–582. https://doi.org/10.1007/s00428-017-2107-1
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506
Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP (2016) Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 96:47–62. https://doi.org/10.1016/j.biomaterials.2016.04.010
He W, Liang P, Guo G, Huang Z, Niu Y, Dong L, Wang C, Zhang J (2016) Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep 6:24506. https://doi.org/10.1038/srep24506
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Additional information
This comment refers to the article available at https://doi.org/10.1007/s00262-017-2090-z.
Rights and permissions
About this article
Cite this article
Pileri, A., Agostinelli, C., Quaglino, P. et al. The role of myeloid derived suppressor cells in mycosis fungoides. Cancer Immunol Immunother 67, 1175–1176 (2018). https://doi.org/10.1007/s00262-018-2153-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-018-2153-9